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Abstract: Bright light therapy (BLT) has demonstrated positive short- and long-term effects in people
with cognitive impairment or dementia; however, the immediate impact of BLT sessions has been
scarcely investigated. In this study, we aimed to explore the immediate effects of BLT on behavior,
mood, and physiological parameters (oxygen saturation/heart rate) in a sample of institutionalized
older adults with moderate to very severe dementia, with a median age of 85.0 (interquartile range,
IQR, 82.0–90.0), being higher in men (87.0 years, IQR 80.0–94.0) than in women (84.5 years, IQR
82.0–89.5). The BLT protocol consisted of 30-min morning sessions of 10,000 lux, Monday through
Friday, for 4 weeks. The physiological parameters were recorded immediately before and after
each session by pulse oximetry. Mood and behavior were assessed before, after, and during the
sessions using the Interact scale. Post-session Interact scores showed a significant decrease in the
items Tearful/sad and Talked spontaneously, and a significant increase in the items Enjoying self, active
or alert, and Relaxed, content or sleeping appropriately. Interact scores during the sessions reflected a
significant decrease in the speech-related items. Both physiological parameters changed positively
from before to after sessions. Our results suggest that BLT provides immediate positive effects
on mood, stimulation level, and physiological parameters, as well as a trend toward decreased
speech. More robust research is needed to further explore the immediate impact of BLT. This study is
registered with Clinicaltrials.gov (NCT04949984).
Keywords: bright light therapy; dementia; mood; behavior; oxygen saturation; heart rate
1. Introduction
Dementia is one of the main causes of disability and dependence among older adults
worldwide, constituting a public health priority due to its significant human and finan-
cial costs to society [1]. Oxidative stress, mitochondrial damage, and synaptic damage
are all implicated in dementia pathogenesis, playing an important role in the cognitive
impairment and memory loss of older individuals with Alzheimer’s disease (AD) [2–4].
Neurotransmitters are essential to maintain synaptic and cognitive function, and are also
involved in altering the mood, depression, or anxiety of AD patients [5,6]. Aside from
cognitive decline, dementia progression leads to the appearance of at least one neuropsy-
chiatric symptom (NPS) in most individuals at some point during the course of their
disease [7,8]. NPS, also known as behavioral and psychological symptoms of dementia
(BPSD) [9], are defined as a series of signs and symptoms of disturbed perception, thought
content, mood, and behavior that frequently occur in dementia and constitute part of the
expression of the disease [10]. These symptoms mainly comprise delusions, hallucinations,
agitation, depression, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor
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behavior, sleep and nighttime behavior disturbances, and changes in appetite and eating
behaviors [11,12].
Treatment development for BPSD includes both pharmacological and nonpharma-
cological therapies. In clinical settings, pharmacological agents are frequently used in
the management of these symptoms but show modest efficacy and significant serious
side-effects [13,14], including increased risks of hospitalization, falls, and mortality [15].
Numerous guidelines and expert recommendations favor nonpharmacological interven-
tions for the treatment of BPSD due to their significant impact on global BPSD outcome
measurements and the lack of adverse events [16]. In fact, the American Geriatrics Society
Beers Criteria Update Expert Panel recommends the use of nonpharmacological approaches
as the first course of action, unless they have previously failed, are not feasible, or there is
a substantial risk of harm to self or others [17]. Therefore, nonpharmacological therapies
should be considered to be the first choice of treatment. Nonpharmacological interventions
include cognitive stimulation, reminiscence therapy, reality orientation, validation therapy,
animal-assisted therapy, exercise or physical activity, Snoezelen/multisensory stimulation,
aromatherapy, music therapy, and light therapy, among others [18,19]. It is necessary for
further research to continue to strengthen the evidence of their effectiveness [16].
In this study, we focus on bright light therapy (BLT). This therapy consists of the
controlled application of certain levels of light that can be administered in different ways,
including outdoor sunlight, light boxes, light visors worn on the head, ceiling lights, or
dawn-dusk simulation [20]. BLT is reported to have positive effects in the management of
BPSD, sleep disturbances, and circadian rhythms (see recent reviews [21,22]). Although
numerous studies address the short- and long-term effects of this therapy in people with
cognitive impairment or dementia, there is little research on its immediate effects. Further-
more, other sensory therapies—such as multisensory stimulation in a Snoezelen room or
music therapy—are shown to provide immediate positive effects on measures of behavior
and mood disturbances, as well as on certain physiological parameters such as heart rate
or blood oxygen saturation [23–25]. Thus, it could be expected that BLT, as a sensory
therapy, would also lead to improvements in mood, behavior, and physiological param-
eters. Therefore, the main objective pursued in this study was to explore the immediate
effects of bright light therapy on behavior, mood, and physiological parameters (oxygen
saturation and heart rate) in a sample of institutionalized older people with moderate to
very severe dementia.
2. Materials and Methods
2.1. Design
This study was designed as a randomized controlled trial. Participants were stratified
according to their cognitive status and were subsequently randomly assigned to the ex-
perimental group (BLT) or control group. In the analysis and exploitation of results, we
only considered the response of the BLT group with regard to the stated objective since the
control group did not undergo the intervention needed to complete Interact assessment
during the study.
2.2. Participants
Participants were recruited from among the residents of a gerontological complex
specializing in dementia (78.7% with cognitive impairment) and located in A Coruña,
Spain. The gerontological complex has 70 older people in a day care-setting and 64 institu-
tionalized older people in a nursing home. We selected all institutionalized participants
(n = 64, with a mean age of 88.4 ± 8.0 years and a median age of 89.0 (interquartile range,
IQR, 84.0–94.0)); 29.7% were men, with a mean age of 88.5 ± 9.4 years and a median age
of 91.0 (interquartile range, IQR, 84.5–94.0), and 70.3% were women, with a mean age of
88.4 ± 7.5 years and a median age of 88.0 (interquartile range, IQR, 84.0–94.0). To delimit
the sample, before the recruitment process, inclusion and exclusion criteria were estab-
lished according to the existing literature. As inclusion criteria, participants were required
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to satisfy the conditions of being 65 years or older, diagnosed with dementia, scoring
≥4 points on the global deterioration scale (GDS) [26], and having signed the informed
consent (directly or through their legal guardians). Based on a recent systematic review on
the ocular safety of light therapy [27], individuals with increased ocular sensitivity to light
(photosensitivity) or those with preexisting ocular abnormalities were excluded from the
study. Residents who had any severe eye disorder that did not allow them to open their
eyes, or involved very low visual acuity, were also excluded since light needed to enter the
participant’s eyes to achieve the desired effects [28].
2.3. Procedure
The research protocol (code 2017/408) received favorable authorization from the
Galician Research Ethics Committee of Xunta de Galicia, Spain, and was developed in
accordance with the Declaration of Helsinki. The participants and their legal guardians
were informed about the study and signed the corresponding informed consent. All the
information transmitted was adapted to the level of comprehension of the participants to
facilitate their understanding and comfort throughout the study.
The study was retrospectively registered with ClinicalTrials.gov (NCT04949984) on
2 July 2021. The study protocol was based on the implementation guidelines that we
described in a recent review [22]. The BLT sessions were carried out in a quiet room of
the gerontological complex especially enabled for their proper implementation and were
conducted by two research psychologists specialized in gerontology. The devices used for
the intervention were bright white light lamps providing an intensity of 10,000 lux. Four
users participated in each session, with two users per lamp, seated in a comfortable chair
with armrests which was 70 cm from the lamp. The sessions were 30 min/day, between
10:30 a.m. and noon, 5 days a week (Monday to Friday), for 4 weeks (total 20 sessions).
During the sessions, while exposed to light, participants watched documentaries on neutral
topics. Each session lasted 30 min, unless the participant expressed the desire to leave the
room and could not be convinced to remain without generating agitation. Participants who
responded negatively to light exposure were immediately withdrawn from the intervention.
Only those sessions in which the participant remained for at least 80% of the expected time
(≥22.5 min) were considered as sessions performed.
In every session, the researchers supervised the participants to ensure full compliance
with the treatment and evaluated the physiological parameters, mood, and behavior of
the participants. Once in the room, the investigators measured the heart rate (beats per
minute) and blood oxygen saturation (SpO2) of each participant using a mobile finger
pulse oximeter before and after the session.
Mood and behavior were assessed during the sessions and in the 10 min periods
immediately before and after each session using the Interact scale [29] and its shortened
version, named Interact short. The Interact scale, hereinafter referred to as Interact during,
is made up of 22 Likert-scale items that score the frequency of occurrence (ranging from
1 (Not at all) to 5 (Nearly all the time)) of each type of mood and behavior during the
sessions. Additionally, as qualitative information, any comments made by the participants
about their session were recorded, as well as the sensation that the researchers believe
the participants experienced during the session (relaxing, stimulating, leisure, improving
communication, arousing curiosity, or unpleasant). The Interact short includes 12 Likert-
scale items, with the same range as in the Interact during, recording the occurrence of each
type of mood and behavior of the participants in the 10 min periods immediately preceding
and following the session to measure any observable change.
2.4. Statistical Analysis
All data were analyzed using the SPSS statistical software package (version 26.0) (IBM,
Armonk, NY, USA) and statistical significance was set at p < 0.05. The normal distribution of
the variables was tested using the Shapiro–Wilk test. For subsequent analyses, we applied
parametric or nonparametric tests depending on whether the assumption of normality was
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met or not for each measured variable. The Wilcoxon signed-rank test or paired t-test were
employed to measure significant changes between the Interact short scores before and after
the intervention sessions for each of the assessed mood and behavior items. Likewise, these
same tests were used to analyze the evolution of the Interact during scores by comparing
the average scores of the first week with those of the fourth week. In addition, the evolution
of mood and behavior scores throughout the four weeks of treatment was analyzed with
the Friedman test for related samples. The paired t-test was also used to determine the
existence of any differences between before and after the sessions in the physiological
parameters investigated. In the variables in which statistically significant differences were
found, Cohen’s d or r values were used to report the effect size (ES) of these changes. The
interpretation of the importance of the ES was made according to the benchmarks defined
by Cohen [30] as follows: small ES (d = 0.2 or r = 0.1), medium ES (d = 0.5 or r = 0.3), and
large ES (d = 0.8 or r = 0.5).
3. Results
3.1. Sample Characteristics
After applying inclusion and exclusion criteria, the total sample was reduced from 64
to 39 institutionalized older people (20 participants assigned to the control group and 19
to the BLT group). Table 1 shows their sociodemographic characteristics and their level
of cognitive decline based on the scores obtained in the GDS. The categorical variables
(gender, marital status, educational level, level of cognitive impairment) are expressed
in terms of frequency and percentage, and age, as a continuous variable, is presented as
the mean plus standard deviation (SD), along with the range of minimum and maximum
values. The mean age of the participants was 86.3 ± 6 years, ranging from 75 to 98, with a
median age of 85.0 (interquartile range, IQR, 82.0–90.0), being higher in men (87.0 years,
IQR 80.0–94.0) than in women (84.5 years, IQR 82.0–89.5). The group was composed mostly
of women (73.7%), and most participants were widowed (68.4%). Concerning educational
level, few of the participants had higher education since most of them had received formal
education for eight or fewer years (73.7%). Regarding the cognitive impairment measured
by GDS, 31.6% of the sample presented moderate decline, 26.3% presented moderate to
severe decline, another 26.3% presented severe decline, and finally, 15.8% of the participants
presented very severe decline.
Table 1. Sociodemographic characteristics of the study population.

















Years of education ≤ 8
Years of education 9–17





Stage 4. Moderate decline
Stage 5. Moderate-severe decline
Stage 6. Severe decline





1 GDS: global deterioration scale.
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3.2. Mood and Behavior
Significant effects were detected between before and after the intervention sessions in
4 of the 12 items evaluated in the Interact short (see Table 2). The results of the Wilcoxon
signed-rank test showed a significant reduction in the prevalence of the Tearful/sad item
(p = 0.044) with a medium effect size (r = −0.32). The results of the paired t-test showed
significant changes in the score of the Talked spontaneously item (p = 0.035) with a medium
effect size (d = 0.52). Moreover, two items of the Stimulation level construct showed a
significant increase in scores: Enjoying self, active or alert (p = 0.034) and Relaxed, content
or sleeping appropriately (p = 0.001), with medium (d = −0.52) and large (d = −0.94) effect
sizes, respectively.
Table 2. Means (SDs) of Interact short scores before and after light therapy sessions.
Construct Item Before After p-value ES
Mood
Tearful/sad a 1.29 (0.46) 1.23 (0.43) 0.044 * r = −0.32
Happy/content b 2.42 (0.88) 2.57 (0.97) 0.052
Fearful/anxious a 1.20 (0.38) 1.08 (0.17) 0.069
Confused a 1.21 (0.38) 1.17 (0.38) 0.128
Speech Talked spontaneously b 2.67 (0.79) 2.53 (0.85) 0.035 * d = 0.52




environment a 4.01 (0.61) 4.09 (0.56) 0.305
Need for prompting Did things from own initiative b 1.88 (0.46) 1.86 (0.44) 0.707
Stimulation level
Wandering, restless or aggressive a 1.10 (0.18) 1.04 (0.07) 0.185
Enjoying self, active or alert b 3.70 (0.64) 3.87 (0.60) 0.034 * d = −0.52
Bored, inactive or sleeping inappropriately a 1.62 (0.66) 1.49 (0.64) 0.052
Relaxed, content or sleeping appropriately b 3.57 (0.55) 3.87 (0.48) 0.001 ** d = −0.94
a Wilcoxon signed-rank test; b paired t-test; * significant (p-value < 0.05); ** significant (p-value < 0.01); ES: effect size (Cohen’s d or r values).
To analyze the significance of the changes in the evolution of behavioral and psycho-
logical symptoms during the sessions, a comparison was made between the mean/median
scores of the Interact during items of the four weeks of intervention. As can be seen in
Table 3, scores reflected a significant decrease in the speech-related items, with large effect
sizes. Scores were significantly lower for the Comments or questions about activities/objects
item of the Relating to the environment construct. The results did not differ when analyzing
the evolution of the four weeks versus the evolution between only the first and last week,
with the same variables being significant in both comparisons.
Regarding the type of experience felt by the participants during the sessions, the
evaluators recorded most of the sessions as leisure (32.98%), followed by relaxing (34.23%),
stimulating (23.35), arousing curiosity (16.18%), and improving communication (6.43%).
The researchers only perceived 6.32% of the sessions as unpleasant for the participants.
3.3. Physiological Parameters
There were significant changes between before and after the sessions in both physi-
ological parameters (see Figure 1). Participants demonstrated an increase in mean SpO2
values (p < 0.001, Figure 1A) and a decrease in mean heart rate (p < 0.001, Figure 1B) at
the end of the sessions, with a large effect size of both changes measured (d = −1.33 and
d = 1.10, respectively).
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Table 3. Means (SDs) of Interact during session scores for each week.
Construct Item Week 1 Week 2 Week 3 Week 4 p-Value ES
Mood
Tearful/sad 1.40 (0.16) 1.27 (0.15) 1.16 (0.08) 1.12 (0.08) 0.675
Happy/content 2.41 (0.25) 2.11 (0.20) 2.15 (0.19) 2.05 (0.22) 0.425
Fearful/anxious 1.16 (0.05) 1.19 (0.15) 1.03 (0.07) 1.08 (0.09) 0.222
Confused 1.06 (0.04) 1.20 (0.08) 1.11 (0.08) 1.03 (0.05) 0.194
Speech
Talked spontaneously 2.42 (0.13) 2.12 (0.29) 2.11 (0.24) 1.96 (0.27) 0.035 * r = −0.43
Recalled Memories 1.04 (0.07) 1.13 (0.12) 1.07 (0.11) 1.05 (0.12) 0.828
Spoke clearly 2.39 (0.14) 2.00 (0.37) 1.85 (0.22) 1.76 (0.06) <0.001 *** d = 0.95
Spoke sensibly 2.39 (0.23) 1.94 (0.34) 1.84 (0.22) 1.76 (0.06) 0.001 ** d = 0.93
Normal length sentences 2.37 (0.13) 1.95 (0.32) 1.85 (0.22) 1.76 (0.06) <0.001 *** d = 0.87
Relating to
person
Held eye contact appropriately 3.36 (0.18) 3.35 (0.39) 3.22 (0.22) 3.16 (0.25) 0.729
Touching 3.03 (0.20) 3.17 (0.29) 3.23 (0.18) 3.04 (0.31) 0.923
Relating well 3.28 (0.24) 3.47 (0.41) 3.55 (0.15) 3.34 (0.20) 0.820
Co-operated 3.46 (0.19) 3.66 (0.45) 3.74 (0.13) 3.57 (0.18) 0.987
Relating to
environment
Tracked Observable Stimuli 3.43 (0.22) 3.51 (0.40) 3.35 (0.21) 3.27 (0.31) 0.907
Touched objects/equipment
appropriately 3.37 (0.20) 3.55 (0.25) 3.45 (0.14) 3.37 (0.23) 0.674
Attentive to/responsive/focused
on activity/objects 3.65 (0.27) 3.68 (0.19) 3.32 (0.32) 3.46 (0.15) 0.220
Comments/questions about
activities/objects 2.13 (0.14) 1.57 (0.16) 1.59 (0.28) 1.42 (0.16) <0.001 *** r = −0.52
Need for
prompting Did things from own initiative 1.99 (0.10) 2.05 (0.19) 1.83 (0.07) 1.97 (0.17) 0.752
Stimulation
level
Wandering, restless or aggressive 1.20 (0.11) 1.05 (0.04) 1.11 (0.06) 1.12 (0.09) 0.204
Enjoying self, active or alert 3.57 (0.23) 3.56 (0.28) 3.33 (0.35) 3.50 (0.10) 0.526
Bored, inactive or sleeping
inappropriately 2.18 (0.18) 2.09 (0.28) 2.43 (0.24) 2.12 (0.28) 0.439
Relaxed, content or sleeping
appropriately 3.54 (0.15) 3.57 (0.13) 3.33 (0.24) 3.61 (0.19) 0.478
* Significant (p-value < 0.05); ** significant (p-value < 0.01); *** significant (p-value < 0.001); ES: effect size (Cohen’s d or r values).
Figure 1. Records of biomedical parameters before and after light therapy intervention from session 0 (baseline) to
20 (post-trial): (A) blood hemoglobin oxygen saturation (%); (B) heart rate—beats per minute (bpm).
4. Discussion
The purpose of this study was to examine the immediate effects of a four-week
BLT intervention program on the behavior, mood, oxygen saturation, and heart rate
of institutionalized older patients with moderate to very severe dementia. The main
results revealed promising evidence of the benefits of BLT on specific aspects of mood and
behavior in participants both during and after the sessions, as well as positive effects on
the physiological parameters analyzed.
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As previously stated, mood and behavior were assessed using the Interact scale [29].
Although this scale was initially developed for the assessment of mood and behavior of
patients with dementia during multisensory stimulation sessions in a Snoezelen room,
its use has been extended to other nonpharmacological interventions such as music [24],
art [31], and reminiscence therapies [32,33]. On this basis, the Interact scale was chosen for
this study since its structure and form of application are also appropriate and compatible
with the procedure of light therapy sessions.
The Interact short scores obtained by the participants before and after BLT sessions
revealed, on the one hand, a significant decrease in the items of Tearful/sad and Talked sponta-
neously, and, on the other hand, a significant change in their stimulation level—specifically
in the items Enjoying self, active or alert, and Relaxed, content or sleeping appropriately. There-
fore, participants were less sad and less spontaneously talkative immediately after BLT
sessions, which in turn could be related to the fact that they were also more relaxed, content,
or sleeping appropriately. Concurring with some of these findings, other authors [34] in-
vestigating the immediate effects of BLT versus dim red light sessions found an immediate
decrease in sleepiness and a tendency for mood improvement upon exposure to bright
light. Other studies using 30-min BLT sessions found short-term positive effects on mood
and agitation in people with dementia [35–37], with greater benefits observed in patients
with severe dementia than in those with mild/moderate dementia [36].
The Interact during showed a significant decrease in the score of the Making comments
or asking questions about the activity item, which makes sense due to the habituation of the
participants to the intervention program as it progressed. Scores on the Interact during also
reflected that as the weeks of intervention progressed, the participants talked less clearly,
sensibly, and spontaneously and with shorter sentences, i.e., an overall decrease in speech
during the sessions. These results may also be linked to the lower post-session scores on
the Talked spontaneously item of the Interact short. None of the existing studies on BLT in the
literature address the immediate effects that occur within sessions, so we cannot discuss
our results from the perspective of previous studies.
Regarding physiological parameters, the measurements showed positive changes
between before and after the sessions in the two analyzed parameters, with a significant
increase in mean SpO2 and a significant reduction in mean heart rate. These changes may
be related to the fact that participants were more relaxed, as shown by the Interact scores,
since these biological responses are considered physiological indicators of a relaxation
response [38,39]. Consistent with our findings, Choi et al. [40], who studied the immediate
influence of different dim-colored lights—white, red, and blue—in healthy adults, also
found a decrease in heart rate after exposure to the illumination. In the existing literature,
another physiological parameter that has been studied with respect to light therapy is
heart rate variability (HRV). A group of authors [41,42] found immediate positive effects
of evening BLT on HRV in a sample of healthy young women. Similar findings were
reported by Rechlin et al. [43] in patients diagnosed with major depression. Our results
differ from another previous study in which no immediate effects of morning BLT on any
of the physiological parameters analyzed were found [34]. Following the initial hypothesis
of this study, our findings on the effects of BLT on the physiological parameters analyzed
coincide with the positive effects of other sensory interventions reported in the existing
literature, such as music therapy [24,25,44,45] and multisensory stimulation [23,24].
To the best of our knowledge, the immediate impact of BLT sessions on mood and
behavior has been virtually unexamined previously, so the present study provides novel
and relevant data for clinical practice. However, the results of this work should be regarded
as preliminary and interpreted with caution due to certain existing limitations. This study
is one part of a larger and more comprehensive BLT investigation. The current study
only analyzed the immediate effects during and after BLT sessions, and the long-term
effects should be further established. Therefore, these limitations stem mainly from the
small sample size and the use of a single-arm intervention with no control group, both
of which limit the generalizability of the results found. Additionally, mood and behavior
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were measured based on the observations of unblinded researchers, which may have
resulted in researcher bias. Future research should address these limitations by employing
a double-blind design in controlled studies with larger sample sizes. Another physiological
parameter (determination of blood pressure at least three times during the sessions) could
also be used to further assess the impact of bright light therapy.
5. Conclusions
The results of the present study suggest that a bright light therapy intervention
program of 30-min sessions provides promising outcomes and immediate positive effects
on mood, stimulation level, blood oxygen saturation, and heart rate. On the other hand,
there was a tendency for a decrease in speech both during and after the intervention
sessions. Further research is needed to strengthen these findings and to explore in depth
the possible immediate effects of BLT.
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